NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma by Han, Seong-Su et al.
Han et al. Molecular Cancer 2010, 9:97
http://www.molecular-cancer.com/content/9/1/97
Open Access RESEARCH
BioMed  Central
© 2010 Han et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B 
lymphoma
Seong-Su Han1, Hwakyung Yun2, Dong-Ju Son1, Van S Tompkins1, Liangping Peng3, Seung-Tae Chung4, Joong-
Su Kim5, Eun-Sung Park6 and Siegfried Janz*1
Abstract
Background: Myc is a well known driver of lymphomagenesis, and Myc-activating chromosomal translocation is the 
recognized hallmark of Burkitt lymphoma, an aggressive form of non-Hodgkin's lymphoma. We developed a model 
that mimics this translocation event by inserting a mouse Myc cDNA gene into the immunoglobulin heavy chain locus, 
just upstream of the intronic Eμ enhancer. These mice, designated iMycEμ, readily develop B-cell lymphoma. To study 
the mechanism of Myc-induced lymphoma, we analyzed signaling pathways in lymphoblastic B-cell lymphomas (LBLs) 
from iMycEμ mice, and an LBL-derived cell line, iMycEμ-1.
Results: Nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) were constitutively 
activated in iMycEμ mice, not only in LBLs but also in the splenic B-lymphocytes of young animals months before 
tumors developed. Moreover, inhibition of either transcription factor in iMycEμ-1 cells suppressed growth and caused 
apoptosis, and the abrogation of NF-κB activity reduced DNA binding by both STAT3 and Myc, as well as Myc 
expression. Inhibition of STAT3 signaling eliminated the activity of both NF-κB and Myc, and resulted in a 
corresponding decrease in the level of Myc. Thus, in iMycEμ-1 cells NF-κB and STAT3 are co-dependent and can both 
regulate Myc. Consistent with this, NF-κB and phosphorylated STAT3 were physically associated with one another. In 
addition, LBLs and iMycEμ-1 cells also showed constitutive AKT phosphorylation. Blocking AKT activation by inhibiting 
PI3K reduced iMycEμ-1 cell proliferation and caused apoptosis, via downregulation of NF-κB and STAT3 activity and a 
reduction of Myc levels. Co-treatment with NF-κB, STAT3 or/and PI3K inhibitors led to additive inhibition of iMycEμ-1 cell 
proliferation, suggesting that these signaling pathways converge.
Conclusions: Our findings support the notion that constitutive activation of NF-κB and STAT3 depends on upstream 
signaling through PI3K, and that this activation is important for cell survival and proliferation, as well as for maintaining 
the level of Myc. Together, these data implicate crosstalk among NF-κB, STAT3 and PI3K in the development of iMycEμ B-
cell lymphomas.
Background
Deregulated NF-κB activity plays a critical role in the sur-
vival and radiation resistance of tumor cells in a variety of
human neoplasias including B cell lymphomas (BCLs) [1-
5]. NF-κB comprises a family of transcription factors that
control genes implicated in B-cell activation, proliferation
and resistance to apoptosis [6]. Five known, structurally
conserved members of the NF-κB/Rel family function as
dimers in various combinations: p50, p52, p65 (Rel A),
Rel B and c-Rel. Classic NF-κB, the p50 and p65 heterodi-
mer, is an activator of gene transcription, whereas the
p50/p50 homodimer both represses and activates the
transcription of target genes [7]. NF-κB exists in an inac-
tive form in the cytoplasm because of its interaction with
the inhibitory protein, IκBα [8]. NF-κB activation is con-
trolled by the IκB kinase (IKK) complex; after stimulation
by cytokines and/or growth factors, IKK phosphorylates
IκB, which results in its subsequent ubiquitination and
proteasomal degradation. The degradation of IκB allows
NF-κB to translocate to the nucleus, where it can activate
or repress target genes [9]. NF-κB not only plays a role in
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the survival of neoplastic B cells, but is also critical for the
development and survival of normal B cells [10].
Another family of transcription factors whose members
are constitutively activated in many human tumors is the
STAT family. These proteins can control various cellular
events such as proliferation, differentiation and cell sur-
vival [11]. One member in particular, STAT3, has been
shown to be constitutively activated in a number of
human tumor cell lines and primary tumors, including
several hematological malignancies [12,13]. STAT3 can
be activated by IL6, interferons, epidermal growth factor
or leptin, through the activity of members of the recep-
tor-associated Janus kinase (JAK) family, which com-
prises JAK1, JAK2, JAK3, or TYK2 [14-16]. JAKs
phosphorylate STAT3 at tyrosine (Tyr)-705, leading to its
dimerization and subsequent translocation to the nucleus
where it activates target genes [17]. In addition, maximal
transcriptional activation of STAT3 requires phosphory-
lation at serine (Ser)-727 in response to cytokine stimula-
tion [18-20].
Yet another important pathway of signal transduction
in B cells and B-cell neoplasms is one involving phos-
phatidyl inositol-3 kinase (PI3K) and AKT. Aberrant acti-
vation of this pathway is a common molecular alteration
in human malignancies [21-25]. PI3K becomes activated
by receptor tyrosine kinases or other cell-surface recep-
tors, resulting in an elevation in the production of the
membrane lipid phospho-inositol (3,4,5)P3 (PIP3) from
phospho-inositol(4,5)P2 (PIP2). The level of PIP3 is nega-
tively controlled by the phosphatase and tensin homolog
(PTEN), which converts PIP3 back to PIP2. AKT binds
PIP3 at the plasma membrane, and this leads to phospho-
rylation of AKT at Ser-473 in its regulatory domain. This
activated form of AKT can then phosphorylate, and
thereby regulate the function of, many cellular proteins
that are involved in cell proliferation and survival, as well
as in tumorigenesis and metastasis [26-30].
Although activation of NF-κB, STAT3 and/or the PI3K/
AKT pathway in B cell neoplasms has been described
[23-25], the mechanism by which these pathways contrib-
ute to the development of BCLs remains unclear, as do
the circumstances under which this occurs. We recently
developed the iMycEμ mouse, an experimental model sys-
tem for studying Myc-driven neoplastic transformation
of B cells. Previous studies have shown that, on a mixed
background of segregating C57BL/6 and 129/SvJ alleles,
the iMyc transgene causes the development of various B
cell-derived lymphomas: lymphoblastic B-cell lympho-
mas (LBLs) in 50% of the mice; diffuse large B-cell lym-
phomas (DLBCLs) in 25% of the mice, and
plasmacytomas (PCTs) in 20% of the mice [31]. In the
study described here, we investigated the role of NF-κB,
STAT3 and PI3K signaling in LBL, the most prevalent
tumor type in the iMycEμ mice. We found that constitu-
tive activation of NF-κB and STAT3 begins well before
frank tumors develop, with co-activation of NF-κB and
STAT3 playing a role in tumor maintenance, and activa-
tion of the PI3K/AKT pathway in the neoplastic B cells
being responsible, in part, for the constitutive activation
of NF-κB and STAT3. Inhibition of any one of these three
pathways resulted in Myc downregulation, inhibited
growth growth and promoted apoptosis in iMycEμ-LBL-
derived cells. We report, for the first time, a physical
association of NF-κB with STAT3 in B cells, and provide
evidence for the convergence of PI3K, NF-κB and STAT3
signaling in Myc-driven lymphomagenesis.
Materials and methods
Tissues and cell lines
Primary LBL tumors from iMycEμ mice [31] and the LBL-
derived cell line, iMycEμ-1 [32], were used in this study.
WEHI 231, RAW 8.1, and NFS-1.0 C-1 cell lines were
purchased from ATCC (Rockville, MD). All cell lines
were maintained in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal bovine serum, 200 mM L-
glutamine, 50 mM 2-mercaptoethanol and antibiotics,
100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco-
BRL, Rockville, MD), at 37°C in a humidified 5% CO2
incubator. Highly enriched (>95% pure) splenic B cells
were isolated from C57BL/6 (BL6) or iMycEμ mice using
CD45R (B220) microbeads and MACS® separation col-
umns (Miltenyi Biotec, Auburn, CA) according to the
manufacturer's protocol. Control cultures were treated
with phosphate-buffered saline (PBS) or DMSO where
appropriate, and the final concentration never exceeded
0.3%.
Preparation of nuclear and cytosolic extracts
Pellets of 107 cells or powdered-frozen LBL samples were
lysed with 400 μl of 10 mM KCl, 0.2 mM EDTA, 1.5 mM
MgCl2, 0.5 mM DTT, and 0.2 mM PMSF at 4°C for 10
minutes. The lysate was centrifuged for 5 minutes at
14,000 × g  and supernatants were stored as cytosolic
extract, at -70°C. The resulting pellet was re-suspended
in 100 μl of ice-cold 20 mM HEPES (pH 7.9), 420 mM
NaCl, 1.5 mM MgCl2, 20% (v/v) glycerol, 0.2 mM EDTA,
0.5 mM DTT, and 0.2 mM PMSF. After incubation at 4°C
for 20 minutes, the lysate was centrifuged for 6 minutes at
14,000 × g, and the supernatant was stored as a nuclear
extract, at -70°C. The concentration of cytosolic and
nuclear extract was determined using a BCA kit (Bio-
Rad, Richmond, CA).
Electrophoretic mobility shift assay (EMSA) and super-shift 
assay
The DNA-protein binding detection kit (Gibco-BRL) was
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were carried out in a final volume of 25 μl of buffer con-
taining 10 mM Tris (pH 7.5), 100 mM NaCl, 1 mM DTT,
1 mM EDTA, 4% (w/v) glycerol, 0.1 mg/ml sonicated
salmon sperm DNA, 10 μg of nuclear extract, and oligo-
nucleotides. Oligonucleotides containing consensus NF-
κB (Promega, Madison, WI), STAT3 (Santa Cruz Bio-
technology, Santa Cruz, CA), or Myc-Max binding sites
(Santa Cruz Biotechnology) were end-labeled to a spe-
cific activity of 105 CPM with γ-[32P]-ATP and T4-poly-
nucleotide kinase, followed by purification on a Nick
column (GE Healthcare, Piscataway, NJ). Reaction mix-
tures with radio-labeled oligonucleotides were incubated
at room temperature for 20 minutes, and resolved on 6%
non-denaturing polyacrylamide gels after addition of 2 μl
bromophenol blue (0.1%). Gels were dried and subjected
to autoradiography. For competition assays, 30-fold
excess unlabeled oligonucleotides containing consensus
or mutated NF-κB, STAT3 or Myc-Max binding sites,
respectively, were added for 20 minutes at room tempera-
ture, after incubation with the radio-labeled oligonucle-
otides. For super-shift assays, 2 μg of antibody (Ab) was
added for 20 minutes at room temperature after the ini-
tial incubation. Abs specific for p50 (sc-114X), p52 (sc-
298X), p65 (sc-109X), RelB (sc-226X), c-Rel (sc-70X),
Myc (sc-764X), SP-1 (sc-59X), STAT3 (sc-483X) or P-
STAT3 (sc-8059X or sc-7993X) were purchased from
Santa Cruz Biotechnology.
Reverse transcription polymerase chain reaction (RT-PCR)
Semi-quantitative RT-PCR was performed by extracting
total RNA using TRIzol (Sigma-Aldrich, St. Louis, MO),
and this was followed by double-stranded cDNA synthe-
sis from 1 μg of total RNA, using the AMV reverse tran-
scriptase kit (Roche, Indianapolis, IN). Thermal cycling
conditions were as follows: 95°C for 5 minutes followed
by 20, 25, 30, 35, or 40 cycles (depending on the target
gene) of amplification at 57°C, 72°C, and 95°C, for 1 min-
ute each. PCR products were resolved by electrophoresis
on 1% agarose gels containing ethidium bromide. Primer
sequences are as follows:
PTEN, forward 5'-GGCGGTGTCATAATGTCTCTCA
-3'
reverse 5'-CCCATTTTCCACTTTTTCTGAGG-3'
β-actin, forward 5'-ATGGCATTGTTACCAACTGG-
GACG-3'
reverse 5'-CTCTTTGATGTCACGCACGATTTC-3'.
Whole-cell extracts and Western blotting
Whole-cell lysates were obtained by re-suspending pel-
lets of 107 cells or powdered-frozen LBL samples in RIPA
buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
10 ng/ml PMSF, 0.03% aprotinin, 1 μM sodium orthovan-
adate) at 4°C for 30 minutes. Lysates were centrifuged for
6 minutes at 14 000 × g, and supernatants were stored at -
70°C as a whole-cell extract. Total protein concentrations
w e r e  d e t e r m i n e d  b y  B C A  ( B i o - R a d ) .  W e s t e r n  b l o t t i n g
was performed with 40 μg of total protein resolved by
SDS-PAGE and transferred to PVDF membranes. Mem-
branes were probed with Abs against c-Myc (sc-764),
PTEN (sc-7974), or IκBα (sc-847) from Santa Cruz Bio-
technology, ERK1/2 (9102), P-ERK1/2 (4377), p38 (9212),
P-p38 (9211), AKT (9272), P-AKT (9271), P-AKT (9275),
p70S6K (9202), or P-p70S6K (9205) from Cell Signaling
(Danvers, MA), α-tubulin (T6074) or β-actin (A5316)
from Sigma-Aldrich. Proteins were visualized using
horseradish peroxidase-conjugated secondary Ab
(1:5000) and the ECL detection kit from Amersham (GE
Healthcare). To confirm equal loading, membranes were
stripped and re-probed using an Ab specific for α-tubulin
or β-actin. Total cell extracts from UV-treated HeLa and
NIH 3T3 cells were used as positive controls for P-ERK1/
2 (sc-2221) and P-p38 (sc-2210), respectively (Santa Cruz
Biotechnology). Total cell extract from insulin-treated
MCF-7 cells was used as a positive control for P-p70S6K
(9203) (Cell Signaling).
Proliferation assay
Proliferation was determined using the Cell Titer 96®
MTS/PMS assay (Promega). Briefly, 3 × 104 cells were re-
suspended in 100 μl growth medium and plated into 96-
well plates (Costar, Cambridge, MA). After 20 hours at
37°C and 5% CO2, 20 μl of MTS/PMS solution was added
to each well and cells were incubated for another 4 hours
before the absorbance at 490 nm was measured on a Mul-
tiskan Spectrum (Thermo Scientific, Hudson, NH).
Apoptosis assay
Apoptosis was evaluated using the DNA fragmentation
assay and fluorescence activated cell sorting (FACS)-
based analysis of propidium iodide (PI), annexin V, and
Caspase-3 reactivity. For DNA fragmentation, DNA was
extracted using the Puregene kit (Gentra Systems, Min-
neapolis, MN) and resolved by electrophoresis on 1.0%
agarose gels containing ethidium bromide. For the identi-
fication of cells with sub-G0/G1 DNA content, cells were
resuspended in PI/Rnase buffer (BD Pharmingen, San
Diego, CA) for 20 minutes at 37°C in the dark before
FACS analysis. Annexin-V reactivity was determined by
applying a phycoerythrin (PE)-labeled Ab (BD Pharmin-
gen) to cells co-stained with 7-amino-actinomycin D (7-
AAD). Activated caspase-3 was detected using a FITC- or
PE-conjugated Ab (BD Pharmingen).
Pharmacological inhibitors
The following small-molecule inhibitors were used:
LY294002 (LY) (Promega); Lactacystin (LC), PD98059
(PD), SB203580 (SB), and rapamycin (Rap) (Biomol,
Plymouth Meeting, PA); WHI P-131 (WHI) and AG 490Han et al. Molecular Cancer 2010, 9:97
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(Biosource, Carlsbad, CA); and AEG 3482 (AEG) (Tocris,
Ellisville, MO).
Co-Immunoprecipitation (Co-IP)
Co-IP was performed using the Universal Magnetic Co-
IP kit according to the manufacturer's protocol (Active
Motif, Carlsbad, CA). Briefly, 500 μg of nuclear extract
was incubated with 5 μg of phosphorylated STAT3 (P-
STAT3) Ab (sc-7993), NF-κB p50 Ab (sc-114), or Rabbit
IgG control (sc-2345) for 3 hour at 4°C. 25 μl of Protein G
Magnetic Beads were added to each tube and then incu-
bated for 1 hour at 4°C. Immunoprecipitates were washed
4 times each with 500 μl wash buffer using a magnetic
stand, after which the pellets were resuspended with 2 ×
reducing loading buffer. Western blot analysis was per-
formed using a primary NF-κB p50 Ab (sc-114) or P-
STAT3 Ab (sc-7993), respectively.
IL6 and IL10 assays
IL6 or IL10 expression was assesssed using the RayBio
Mouse Cytokine Antibody Array III kit (RayBiotech, Nor-
cross, GA) or the Mouse IL-6 or IL-10 Enzyme-Linked
Immunosorbent Assay (ELISA) kit (eBioscience, San
Diego, CA), according to the manufacturer's protocol.
Samples tested were 107 splenic B or B220-negative cells
from 2-month-old BL6 or iMycEμ  mice, separated by
CD45R (B220) microbeads and MACS® separation col-
umns (Miltenyi Biotec).
Results
NF-κB and STAT3 are constitutively activated in B-cell 
lymphomas of iMycEμ mice
Both NF-κB and STAT3 are important for the prolifera-
tion and survival of normal B cells and several types of
non-Hodgkin's lymphoma (NHL) [33-37]. We used
EMSA to examine NF-κB and STAT3 activity in both
iMycEμ-derived LBLs and the iMycEμ-1 cell line. All nine
LBLs and the iMycEμ-1 cells showed abnormal activation
of both NF-κB (Figure 1A) and STAT3 (Figure 1B) when
compared to isolated splenic B cells from control C57BL/
6 (BL6) mice.
To ascertain the specificity and subunit composition of
NF-κB, we conducted competition and super-shift assays
on iMycEμ-1 cells. Incubation of nuclear extracts with 30-
fold excess unlabelled competitor probe abolished the
constitutive NF-κB activity, but incubation with unla-
belled probes containing a mutation that disables NF-κB
binding (mutator) did not (Figure 1C, left), indicating that
the observed band was indeed NF-κB. Super-shift assays
were carried out using antibodies (Ab) against NF-κB
subunit p 50, p 52, p 65, Rel B, or c-Rel. As shown in the
right panel of figure 1C, notable shifts were observed
when antibodies against p50 (lane 2), p 65 (lane 4) or c-
Rel (lane 6) were added. The p50 Ab shifted both NF-κB-
specific bands to higher molecular-weight positions,
whereas the p 65 and c-Rel antibodies shifted only the
upper band. Neither the p 52 nore the RelB antibody pro-
duced any shift. These results indicate that the constitu-
tively activated NF-κB in iMycEμ-1 cells is likely
comprised of p 50/p 50 homodimers and/or p 50/p 65
and p 50/c-Rel heterodimers. That the observed shift
involving p65 was less pronounced suggests that p 50/p
50 and p 50/c-Rel complexes predominate.
Competition and super-shift assays were also per-
formed for ST A T3. Incubation of nuclear extracts with
competitor abrogated the constitutive STAT3 activity,
whereas the addition of mutator did not (Figure 1D, left).
Incubation with one Ab specific for STAT3 phosphory-
lated at Tyr-705 shifted the band to a higher molecular
weight, and incubation with another Ab completely elim-
inated the STAT3 band (Figure 1D, right, lanes 2 and 3,
respectively). These results show that the activated form
of STAT3 is phosphorylated on Tyr-705. Myc Ab and SP1
Ab were used as negative controls and did not show any
change.
Constitutive activation of NF-κB and STAT3 occurs early in 
iMycEμ mice
The use of mouse models offers a valuable opportunity to
study early events that contribute to tumor development.
To determine whether NF-κB and STAT3 activation
occurred before tumors were present, we examined NF-
κB and STAT3 activity in splenic B cells from tumor-free
(premalignant) or tumor-bearing (malignant) iMycEμ
mice, using splenomegaly and age as two independent
indicators of tumor progression. As expected, NF-κB
(Figure 2A) and STAT3 (Figure 2B) activity was increased
i n  s p l e n i c  B  c e l l s  i s o l a t e d  f r o m  m i c e  w i t h  m a l i g n a n t
growths (i.e. mice with spleen masses of on average 750
mg) relative to that in splenic B cells from normal BL6
mice (i.e. spleen masses between 80-100 mg). However,
splenic B cells from iMycEμ mice with no visible signs of
malignancy and spleen masses between 80-150 mg,
which were considered premalignant, also had abnor-
mally high NF-κB and STAT3 activity. Similarly, splenic B
cells from one to four month-old premalignant iMycEμ
mice (as defined without regard to spleen weight) exhib-
ited highly elevated NF-κB and STAT3 DNA-binding
activity, at as early as one month of age, relative to splenic
B cells from age-matched, normal BL6 mice (see addi-
tional file 1A and 1B). These data show that constitutive
activation of both NF-κB and STAT3 occurs months
before tumors are present, and at an early age, in iMycEμ
mice [31].
We also evaluated the level of Myc protein in splenic B
cells of premalignant and malignant iMycEμ  mice (asHan et al. Molecular Cancer 2010, 9:97
http://www.molecular-cancer.com/content/9/1/97
Page 5 of 17
defined by spleen size), as well as in iMycEμ-1 cells (Figure
2C). It is widely accepted that the cellular level of Myc
must remain exquisitely titrated to induce neoplastic
development but avoid apoptosis [38]. Consistent with
this, only a marginal elevation of Myc protein was repeat-
edly observed in premalignant iMycEμ B splenocytes. Myc
protein was, however, dramatically elevated in malignant
B cells and in iMycEμ-1 cells. Even though NF-κB and
STAT3 are known to drive Myc expression [34,38-41],
constitutive activity of NF-κB and STAT3 is not sufficient
to increase the level of Myc at premalignancy in iMycEμ B
cells.
IL6 and IL10 are important cytokines that have been
implicated in lymphomagenesis and are linked to NF-κB
and STAT3 signaling through autocrine and/or paracrine
loops [4,14,39]. We performed cytokine array and ELISA
t o  e x a m i n e  w h e t h e r  e l e v a t e d  e x p r e s s i o n  o f  I L 6  a n d / o r
IL10 are involved in early activation of NF-κB and STAT3
in iMycEμ mice. As shown in Figure 2D, no significant dif-
ference was observed in the level of either IL6 or IL10
between the splenic B cells of BL6 and premalignant
iMycEμ mice, suggesting that elevated levels of IL6 and
IL10 are not responsible for elevated NF-κB or STAT3
activity through autocrine signaling. IL6 and IL10 expres-
Figure 1 NF-κB and STAT3 are constitutively activated in LBLs and iMycEμ-1 cells. (A and B) EMSA using an NF-κB-specific probe (A) and a STAT3-
specific probe (B), respectively, showing constitutive DNA-binding by NF-κB and STAT3 in LBL tumors (left panel), iMycEμ-1 cells (right panel) and con-
trol (C) C57BL/6 splenic B cells. (C) EMSA competition assay (left panel) demonstrating specificity of NF-κB probe. Right panel shows a super-shift assay 
for NF-κB, using antibodies (Abs) specific for the denoted subunits. Asterisks denote non-specific bands that are covered by the super-shifted bands 
in lanes 2 and 6. (D) Competition (left panel) and super-shift (right panel) assays for STAT3. Competitor is an unlabelled oligonucleotide probe, and 
mutator is an unlabelled probe with a mutation that abrogates DNA-binding. P-STAT3 super-shift Abs are both specific for phosphorylated STAT3 at 
Tyr-705; Ab 1 is sc-7993X and Ab 2 is sc-8059X. SP1 and Myc Abs were used as negative controls. Arrowheads denote shifted bands. Images are rep-
resentative, and image splicing was carried out only for the same experiment, the same gel and the same exposure times.Han et al. Molecular Cancer 2010, 9:97
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Figure 2 Constitutive activation of NF-κB and STAT3 in iMycEμ mice occurs early. (A and B) EMSA showing elevated DNA-binding activity of NF-
κB (A) and STAT3 (B), respectively, in both premalignant (average spleen weight 80-150 mg) and malignant (average spleen weight ~750 mg) splenic 
B220-positive B cells from iMycEμ and control BL6 (average spleen weight 80-100 mg) mice. (C) Western blot showing the level of Myc protein in con-
trol, premalignant and malignant splenic B cells, defined as above, and in iMycEμ-1 cells. β-actin was used as a loading control. (D and E) Cytokine array 
(Left panel) and ELISA (Right panel) for IL6 and IL10, showing the levels of IL6 and IL10 protein in splenic B cells (D) and in splenic B220-negative cells 
(E) from 2-month old control or iMycEμ mice. ImageQuant software was used to quantitate the results of cytokine array, and data are expressed as 
arbitrary densitometric units (AU) after normalization to positive controls (Pos). "Neg" denotes negative controls.Han et al. Molecular Cancer 2010, 9:97
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sion was also nearly equivalent in splenic B220-negative
cells from premalignant iMycEμ and control mice (Figure
2F), suggesting that IL6 and IL10 are not upregulated in
the B-cell microenvironment. Additionally, we indepen-
dently evaluated the levels of IL6 and IL10 in LBL tumors
using RT-PCR, GEArray (SA Bioscience, Frederick, MD)
and Affymetrix GeneChip Arrays (Affymatrix, Santa
Clara, CA) (n = 11, 8 and 4, respectively). No elevation of
IL6 and IL10 expression has been observed in these
iMycEμ tumors compared to normal BL6 splenic B cells
(data not shown). These data suggest that the overexpres-
sion of IL6 and IL10 does not occur as a response to ele-
vated NF-κB or STAT3 activity, nor as a cause thereof,
through either autocrine or paracrine signaling in iMycEμ
mice.
Inhibition of NF-κB in iMycEμ-1 cells reduces cell 
proliferation, causes apoptosis, and downregulates STAT3 
activity and Myc expression
To investigate the role of NF-κB in proliferation and sur-
vival, we cultured iMycEμ-1 cells in the presence of the
NF-κB inhibitor, Lactacystin (LC). LC treatment for 24
hours inhibited growth of iMycEμ-1 cells in dose-depen-
dent fashion, as measured by MTS (Figure 3A). DNA lad-
dering indicated that LC also induced apoptosis (Figure
3D). By EMSA, we confirmed that 5 μM LC inhibited NF-
κB activity (Figure 3C) by stabilizing IκB (Figure 3D).
Notably, other NF-κB inhibitors, BAY-11 7085 or Hele-
nin, which function by blocking IκB phosphorylation or
preventing DNA-binding by NF-κB, respectively, had
similar inhibitory effects on the proliferation of iMycEμ-1
cells (data not shown). We then examined whether inhib-
iting NF-κB altered STAT3 or Myc activity. As shown in
Figure 3E and 3F, treatment with LC dramatically
reduced the activity of both STAT3 and Myc. The reduc-
t i o n  i n  M y c  a c t i v i t y  c o r r e s p o n d e d  t o  a  r e m a r k a b l e
decrease in the level of Myc protein (Figure 3G). EMSA
competition and super-shift assays were done as before,
to demonstrate the specificity of Myc DNA-binding (see
additional file 2). These data imply that NF-κB is neces-
sary for the proliferation and survival of iMycEμ-1 cells,
and to link NF-κB to the activities of STAT3 and Myc.
STAT3 is required for optimal proliferation and survival of 
iMycEμ-1 cells, and is linked to activation of NF-κB and Myc
STAT3 was also constitutively activated in iMycEμ LBLs,
so we examined whether signaling through this transcrip-
tion factor is important for the proliferation and survival
of iMycEμ-1 cells. Cells were cultured in the presence of
the potent JAK3/STAT3 specific inhibitor WHI P-131
(WHI), and this suppressed growth in a dose-dependent
manner (Figure 4A) and ultimately led to apoptosis (Fig-
ure 4B) through abrogation of STAT3 activity (Figure 4C).
Use of the potent JAK2/STAT3-specific inhibitor AG 490
resulted in similar inhibitory effects on the proliferation
of iMycEμ-1 cells (data not shown). We then assessed
whether STAT3 signaling had an effect on NF-κB and/or
Myc activity. Inhibiting STAT3 severely reduced the DNA
binding activity of both NF-κB (Figure 4D) and Myc (Fig-
ure 4E), and led to a reduction in Myc protein levels (Fig-
ure 4F). Like NF-κB, STAT3 appears to be necessary for
the proliferation and survival of iMycEμ-1 cells. Thus
STAT3 is reciprocally linked to NF-κB activity and has
similar effects on Myc, a finding that intimates a co-
dependency between NF-κB and STAT3 signaling.
NF-κB and phosphorylated STAT3 associate physically in 
iMycEμ-1 cells
Recent studies have shown that NF-κB and STAT3 physi-
cally associate with one another in several cell types [42-
46]. Our findings indicate that constitutively activated
NF-κB and STAT3 may cooperatively regulate each other.
Thus, we investigated whether STAT3 and NF-κB are
physically associated in iMycEμ-1 cells. Super-shift assays
were performed with a STAT3-specific oligonucleotide
probe and antibodies specific for p 50, p 65, or c-Rel NF-
κB subunits. As shown in Figure 5A, our results showed a
clear shift in DNA-bound STAT3 when a p 50 Ab was
added (lane 2). Addition of a p 65 Ab (lane 3) or c-Rel Ab
(lane 4) led to a slight decrease in band intensity (~1/3 of
control). This suggests that p65 and c-Rel may be
involved in the complex, consistent with our previous
observation of shifts in NF-κB DNA-binding with these
subunits (see Figure 1C). In the reciprocal experiment,
only the addition of an anti-STAT3 Ab (Figure 5B, lane 2)
or a P-STAT3 (Tyr 705) Ab (lane 3) affected DNA-bind-
ing of NF-κB. These super-shift results indicate that NF-
κB and P-STAT3 are physically associated. For further
verification, we performed Co-IP and Western blotting
for P-STAT3 or the p50 subunit of NF-κB. In keeping
with the super-shift results, NF-κB and P-STAT3 were
co-immunoprecipitated (Figure 5C). Thus, NF-κB and
STAT3 reside in the same complex in iMycEμ-1 cells.
AKT is aberrantly activated in LBLs and iMycEμ-1 cells
Having observed signaling crosstalk between constitu-
tively activated NF-κB and STAT3, we investigated the
role of some other major signaling pathways in LBLs and
iMycEμ-1 cells. Given that PI3K, mTOR and MAPK sig-
naling are important for cell survival and proliferation
[21-25], we examined activation of these pathways. The
PI3K downstream effector AKT was phosphorylated on
both Ser-473 and threonine (Thr)-308 in nearly all LBLs
and iMycEμ-1 cells, indicating that it was constitutively
activated (Figure 6A). In contrast, phosphorylated forms
of ERK, p38 and p70S6K were not readily apparent, indi-Han et al. Molecular Cancer 2010, 9:97
http://www.molecular-cancer.com/content/9/1/97
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cating that the MAPK and mTOR signaling pathways
were not activated. In many types of tumors, the loss or
mutation of PTEN leads to elevated activity of the PI3K/
AKT pathway [47]. Thus, we evaluated the PTEN levels
in LBLs and iMycEμ-1 cells by Western blotting and RT-
PCR. PTEN protein or mRNA remained unchanged
compared to levels in normal splenic B cells (Figure 6B
and 6C, respectively). Activation of AKT from these par-
ticular tumor samples and quantitation of PTEN mRNA
are shown in additional file 3. Sequencing of PTEN
showed no mutation in the Pten gene in either LBLs or
iMycEμ-1 cells (data not shown). Additionally, because
activating mutations of PIK3CA can result in the consti-
tutive phosphorylation and activation of AKT [48], we
sequenced the Pik3ca  gene. However, we did not find
mutations in this gene in any LBLs or iMycEμ-1 cells (data
not shown). These results suggest that constitutive acti-
vation of the AKT, but not mTOR or MAPK, pathways is
involved in the pathogenesis of iMycEμ lymphoma, inde-
pendent of loss or mutation of either Pten or Pik3ca.
Figure 3 NF-κB inhibition suppresses growth, causes apoptosis and downregulates STAT3 and Myc activity in iMycEμ-1 cells. (A) MTS/PMS 
cell proliferation assay, after culture with the NF-kB inhibitor lactacystin (LC) at various concentrations as indicated. Data were normalized to vehicle 
control, and error bars represent the standard deviation from a representative experiment performed in triplicate. (B) Agarose gel showing DNA frag-
mentation in sample treated with LC, but not in PBS control. (C) EMSA showing reduced NF-κB DNA-binding after LC treatment. (D) Stabilization of 
IκB protein after treatment with LC, as determined by Western blotting. (E) Reduced STAT3 DNA-binding activity after NF-κB inhibition, as observed 
by EMSA. (F) EMSA showing that Myc DNA-binding activity is reduced after LC treatment. (G) Western blot showing that Myc protein levels are reduced 
after NF-κB inhibition. β-actin was used as a loading control for Western blots. All LC incubations were for 24 hours.Han et al. Molecular Cancer 2010, 9:97
http://www.molecular-cancer.com/content/9/1/97
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PI3K/AKT is important for the proliferation and survival of 
iMycEμ-1 cells and is linked to the NF-κB and STAT3 
activation, as well as to Myc regulation
To determine whether constitutive activation of the
PI3K/AKT pathway plays a critical role in the prolifera-
tion and survival of iMycEμ-1 cells, we cultured them in
the presence of the PI3K inhibitor LY294002 (LY). Treat-
ment with LY substantially reduced phosphorylation of
AKT (Figure 7A), and resulted in growth suppression
(Figure 7B, see additional file 4A) and apoptosis (Figure
Figure 4 STAT3 inhibition reduces growth, leads to apoptosis and downregulates NF-κB and Myc activity in iMycEμ-1 cells. (A) Dose-depen-
dent suppression of proliferation (MTS/PMS) after culture with the STAT3 inhibitor WHI P-131 (WHI) at various concentrations, as indicated. Data were 
normalized to DMSO treatment controls, and error bars represent the standard deviation for a representative experiment performed in triplicate. (B) 
Agarose gel showing DNA fragmentation after treatment with WHI. (C, D and E) EMSA revealing reduced STAT3 (C), NF-κB (D) and Myc (E) DNA-bind-
ing, respectively, after WHI treatment. (F) Western blot showing a decrease in the level of Myc protein after STAT3 inhibition. β-actin was used as a 
loading control. All WHI incubations were for 24 hours.Han et al. Molecular Cancer 2010, 9:97
http://www.molecular-cancer.com/content/9/1/97
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7C, see additional file 4B). In keeping with the Western
blot results (see Figure 6A), inhibition of ERK by
PD98059 (PD), of p38 by SB203580 (SB), of mTOR by
rapamycin (Rap), or of JNK by AEG 3482 (AEG) had a
marginal to no effect on iMycEμ-1 cell proliferation (Fig-
ure 7B, see additional file 4B and 4C). These results show
that the PI3K/AKT pathway, but not the MAPK or mTOR
pathways, plays an important role in the proliferation and
survival of iMycEμ-1 cells. The requirement of PI3K/AKT
signaling for constitutive activation of NF-κB, STAT3 and
Myc was then examined by EMSA. Inhibition of PI3K sig-
nificantly reduced NF-κB, STAT3 and Myc activity (Fig-
ure 7D) and also led to a reduction of Myc protein (Figure
Figure 5 NF-κB and STAT3 associate with one another physically 
in iMycEμ-1 cells. (A and B) EMSA super-shift assays performed with 
STAT3-specific probes and NF-κB-specific Abs (A), or NF-κB-specific 
probes and STAT3-specific Abs (B). Abs were specific for NF-κB sub-
units, Tyr-705 phosphorylated STAT3 (P-STAT3) and total STAT3, as in-
dicated. Abs against SP1 and Myc were used as negative controls. (C) 
Co-IP and Western blot showing co-immunoprecipitation of NF-κB 
p50 and P-STAT3. Abs used for immunoprecipitations (IP) and Western 
blotting (WB) are designated. Images are representative, and image 
splicing was only carried out only for the same experiment, the same 
gel and the same exposure times.
Figure 6 AKT is constitutively phosphorylated, in a PTEN inde-
pendent-manner, in a majority of LBLs and iMycEμ-1 cells. (A) 
Western blot analysis of the activating-phosphorylation status of key 
proteins of the PI3K (AKT, P-AKT S473 and T308), MAPK (ERK 1/2, P-
ERK1/2, total p 38, P-p 38) and mTOR (p70S6K, P-p70S6K) signaling 
pathways. Positive controls for P-ERK1/2, P-p38 and P-p70S6K were 
from extracts of UV-treated HeLa cells, NIH 3T3 cells and insulin-treated 
MCF-7 cells, respectively. (B and C) Levels of PTEN protein (B) and 
mRNA (C) in LBLs and iMycEμ-1. α-tubulin and β-actin served as loading 
controls, respectively. "C" denotes control BL6 splenic B cells.Han et al. Molecular Cancer 2010, 9:97
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Figure 7 PI3K inhibition diminishes NF-κB, STAT3 and Myc activity in iMycEμ-1 cells, and reduces their proliferation and survival. (A) Western 
blot showing the levels of total AKT, PTEN and phosphorylated AKT (S473 and T308) after treatment with LY294002 (LY). α-tubulin was used as a load-
ing control. (B) MTS/PMS assay after treatment with vehicle control, LY, PD98059 (PD), SB203580 (SB), rapamycin (Rap), or AEG 3482 (AEG) at the indi-
cated concentrations. Data were normalized to DMSO-treatment controls, and error bars represent the standard deviation from a representative 
experiment performed in triplicate. (C) Representative FACS analyses on LY- (open grey histogram) or DMSO- (filled black histogram) treated cells 
showing an increase in sub-G0/G1 DNA, as assessed by propidium idodide (PI) staining (left panel), and apoptosis as assessed by increases in both 
Annexin V (middle panel) and activated caspase 3 (right panel) staining. (D) EMSA showing reduced DNA-binding activity of NF-κB, STAT3 and Myc 
after treatment with LY, but not PD, SB, AEG or Rap. (E) Western blot demonstrating reduced Myc protein levles after inhibition of PI3K; α-tubulin served 
as a loading control. (F) NF-κB, STAT3 and Myc DNA-binding activity is reduced in a time-dependent manner after PI3K is inhibited with LY. The incu-
bation time with small-molecule inhibitors was 24 hours unless otherwise indicated.Han et al. Molecular Cancer 2010, 9:97
http://www.molecular-cancer.com/content/9/1/97
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7E). These effects were identical to those seen following
the inhibition of either NF-κB (see Figure 3) or STAT3
(see Figure 4) alone, strongly suggesting crosstalk
amongst PI3K/AKT, NF-κB and STAT3.
So far our studies had only looked at a snapshot of tran-
scription-factor activity, so we evaluated whether the
activity of NF-κB, STAT3 and/or Myc were temporally
regulated as a result of PI3K signaling in iMycEμ-1 cells.
Differential timing could hint at the order in which these
transcription factors might influence one another. The
DNA-binding activity of NF-κB and STAT3 diminished
with identical kinetics, beginning about six hours after
treatment with LY (Figure 7F). Notably, the inhibition of
Myc activity was delayed by about two hours compared to
inhibition by NF-κB and STAT3 (Figure 7F). These
results are in harmony with the possibility that signaling
progresses from PI3K to NF-κB and STAT3, which then
regulate Myc.
PI3K, NF-κB and/or STAT3 inhibitors have an additive, 
rather than synergistic, inhibitory effect on iMycEμ-1 cell 
proliferation
Co-treatment with inhibitors of different signaling path-
ways can provide useful information regarding intracellu-
lar pathway linkage and signal transduction. Because our
results have shown that inhibition of any one pathway -
PI3K, NF-κB or STAT3 - suppresses proliferation and
causes apoptosis, we tested whether co-treatment with
inhibitors against these pathways leads to synergitic
effects, as has been reported for to be the case for NF-κB
and STAT3 [49]. Synergism between these inhibitors
would indicate that the target genes (not evaluated here)
elicited by NF-κB and STAT3 individually have a greater
effect on cell survival and proliferation than the set of tar-
get genes elicited by convergent NF-κB/STAT3 signaling.
T o test this possibility , we cultured iMyc Eμ-1 cells with
low doses of LC, WHI or LY, which individually cause
only a very weak or a modest inhibition of proliferation
(Figure 8, lanes 2-4). Regardless of the co-treatment com-
bination, an additive, rather than synergistic, effect was
observed (Figure 8, compare lane 5 to lanes 2 and 3, lane
6 to lanes 2 and 4, lane 7 to lanes 3 and 4). Considering
that there is a certain dependence of both NF-κB and
STAT3 on PI3K signaling (see Figure 7), and that NF-κB
and STAT3 are physically located in the same molecular
complex (see Figure 5), these results suggest that PI3K,
NF-κB and STAT3 converge in Myc-driven lymphoma.
Discussion
An enhanced understanding of the signal transduction
pathways underlying the development of B-cell neo-
plasms is an important step towards identifying novel tar-
gets for tumor therapy and prevention. Although
previous studies have demonstrated that NF-κB, STAT3
and/or PI3K play critical roles in growth control, survival,
and chemotherapy resistance of B-cell and plasma-cell
neoplasms [50-52], the precise function of NF-κB, STAT3
and/or PI3K in the development of these tumors is not
completely understood. In this study, we used the iMycEμ
LBL model to uncover signaling crosstalk between NF-
κB, STAT3 and PI3K signaling. To our knowledge, this is
the first report of crosstalk amongst these pathways in B
lymphoma cells. We found that constitutive activation of
the PI3K/AKT, but not the mTOR or MAPK pathways,
was found to be at least partially responsible for aberrant
NF-κB and STAT3 activity. Inhibition of NF-κB, STAT3
or PI3K signaling in iMycEμ B cells, respectively, led to
growth suppression, apoptosis and downregulation of
Myc. Combined inhibition had an additive effect on pro-
liferation, suggesting that NF-κB and STAT3 converge
downstream of PI3K. Our finding that NF-κB and STAT3
are physically associated in iMycEμ-1 B cells supports this
interpretation. Signaling crosstalk of NF-κB, STAT3 and
PI3K may play an important role in Myc-induced B-cell
lymphoma in mice.
The finding that NF-κB, STAT3 and PI3K are constitu-
tively activated in LBLs and iMycEμ-1 cells is in keeping
with the aberrant activity of these pathways observed in
various types of B cell neoplasms. Constitutive activation
of NF-κB has frequently been observed in follicular lym-
phoma [53,54], DLBCL [55], mucosa-associated lym-
phoid tissue (MALT) lymphoma [56], multiple myeloma
Figure 8 Co-treatment with small-molecule inhibitors of NF-κB, 
STAT3 and/or PI3K additively inhibits the proliferation of iMycEμ-
1 cells. MTS/PMS cell proliferation assay after 24-hour treatment with 
low doses of LY, LC and WHI in isolation or in various combinations, as 
indicated. Box at the bottom gives the average percent (%) growth in-
hibition. Data were normalized to DMSO-treatment controls, and error 
bars represent the standard deviation from a representative experi-
ment performed in triplicate.Han et al. Molecular Cancer 2010, 9:97
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(MM) [57], and mantle-cell lymphoma (MCL), as well as
MCL cell lines, in which inhibition of this constitutive
activation induces growth arrest and apoptosis [58-60].
Aberrant STAT3 activation has been documented in MM
[61], Hodgkin's disease [62], anaplastic lymphoma kinase-
positive (ALK) DLBCL [63], and activated B-cell (ABC)
DLBCL, in which JAK2/STAT3 inhibitors trigger arrest
and apoptosis [40]. Activation of the PI3K pathway is one
of the most common defects in human malignancies,
including Burkitt's lymphoma, MCL, and Hodgkin's lym-
phoma [21-25]. The repeated discovery of the involve-
ment of NF-κB, STAT3 and PI3K in distinct forms of B-
cell neoplasias underscores the importance of these sig-
naling pathways in B-cell transformation.
Several findings support crosstalk among NF-κB,
STAT3 and PI3K signaling in the iMycEμ system. Inhibi-
tion of NF-κB abrogated constitutive STAT3 activity,
inhibition of STAT3 reciprocally reduced constitutive
NF-κB activity, and inhibition of PI3K suppressed activa-
tion of both NF-κB and STAT3 in iMycEμ-1 cells. When
inhibitor combinations affecting NF-κB and STAT3 or
either and PI3K were applied, additive suppression of
proliferation was observed, indicating that the NF-κB and
STAT3 pathways converge. The physical association
between the active forms of NF-κB and STAT3 in iMycEμ-
1 cells provides direct evidence for such crosstalk and
convergence. Partial characterization of this complex
revealed interactions between the NF-κB subunits p50,
p65, and/or c-Rel, either directly or indirectly, with phos-
phorylated STAT3. The exact compositions of the com-
plexes, and the ultimate functions of these interactions,
are not yet defined. Although crosstalk among transcrip-
tion factors is a common mode of gene regulation, and
several studies have already reported physical and func-
tional interactions between NF-κB and STAT3 in various
cell types [42-46,64-66], to our knowledge, this is the first
description of a physical association between NF-κB and
STAT3 in neoplastic B cells. A recent study showed that
constitutive STAT3 activity can maintain constitutive
NF-κB activity in solid tumors [46], and our finding sup-
ports the possibility of a reciprocal activity of NF-κB and
STAT3 in the maintenance of hematopoietic tumors.
We have explored the potential involvement of other
pathways in the proliferation and survival of iMycEμ -1
cells and on NF-κB and STAT3 signaling, but found that
only the PI3K pathway was involved. It is very interesting
that the Eμ-myc model of B-cell lymphoma, one of the
earliest transgenic mice ever developed to still be widely
used today [67], also showed a requirement for PI3K, but
n o t  m T O R  o r  E R K,  a c t i v i t y  i n  m i t o g e n - i n d u c e d  B - c e l l
growth [68]. This suggests that the PI3K pathway may be
a key modulator of Myc-driven B cell lymphomagenesis.
Moreover, inhibition of PI3K abrogated STAT3 and NF-
κB activity, and simultaneous inhibition of PI3K with NF-
κB or ST A T3 resulted in an additive growth inhibition,
i m p l y i n g  t h a t  P I 3 K  f u n c t i o n s  u p s t r e a m  o f  N F - κ B  a n d
STAT3 in iMycEμ B cells. To follow up on how PI3K might
be constitutively activated, we assessed the known causes
of aberrant PI3K activity - loss or mutation of Pten [69-
71] or mutation of Pi3kca [47,48,72,73] - but did not find
these alterations in either LBLs or iMycEμ-1 cells. This
finding is consistent with other studies indicating that
neither PTEN nor PI3KCA is involved in B-cell malignan-
cies [74,75]. The reason for constitutive activation of
PI3K remains to be determined.
In keeping with our results, crosstalk among NF-κB,
STAT3 and PI3K signaling is supported in the literature.
Notable examples include AKT-mediated phosphoryla-
tion of IKK to activate NF-κB [76,77], IL-2-mediated
induction of PI3K upstream of STAT3 activation in pri-
mary human T cells [78], and the physical interaction
between the PI3K p85 subunit and STAT3 during STAT3
activation [79]. Furthermore, AKT, NF-κB and STAT3
signaling are required for the growth of lymphomas
driven by the expression of Epstein-Barr Virus latent
membrane protein 1 (EBV-LMP1) [50], and also for the
survival of chronic lymphocytic leukemia (CLL) B cells
[51]. Intriguingly, several recent reports describe a role
for p300, an acetyltransferase, as a potential mediator of
signaling crosstalk of NF-κB, STAT3 and PI3K/AKT.
AKT-mediated phosphorylation of p300 dramatically
increases its acetyltransferase activity and can increase
acetylation and full transcriptional activation of p65
[80,81]. For STAT3, leukemia inhibitory factor (LIF)- or
IL6-mediated activation of AKT can lead to phosphoryla-
tion of p300, and to subsequent acetylation and activation
of STAT3 in 293T and Hep3B cells [65,82,83]. Also, acety-
lation of p65 by p300 is facilitated by STAT3 and can lead
to enhanced nuclear localization of p65 [46]. Although
proof the involvement of p300 in iMycEμ B-cell neoplasia
has not yet been demonstrated, p300 is a prime candidate
to link the crosstalk of PI3K, NF-κB, and STAT3 signal-
ing, and is of considerable interest for future studies.
To demonstrate that our results are not unique to
iMycEμ-1 cells, we investigated whether similar signal
transduction pathways were important for tumor mainte-
nance in other mouse B-lymphoma lines (see additional
files 5, 6, &7). Strikingly similar inhibitor sensitivity was
seen in WEHI 231 and iMycEμ-1 cells. In fact, the sort of
PI3K/NF-κB/STAT3 signaling crosstalk seen in iMycEμ-1
cells was also observed in WEHI 231 cells when we
repeated many of the same experiments (see additional
files 6 and 7). These findings argue that our results are
not a peculiarity of iMycEμ-1 cells, and also make a strong
case for the specificity of the small-molecule inhibitors
used in our studies.
Premalignant B cells are difficult to obtain from
humans, but mouse models, such as iMycEμ are a readyHan et al. Molecular Cancer 2010, 9:97
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source of these cells and can be used to elucidate the tem-
poral regulation of molecular events in the course of lym-
phoma development. We found that NF-κB and STAT3
were already constitutively activated in splenic B cells of
iMycEμ mice months before overt tumors developed. The
literature would suggest that this early activation of NF-
kB and STAT3 is caused by an increase in IL6 and/or IL10
[4,44,49]. Our data are novel because they exclude the
possibility of elevated IL6 or IL10 from either autocrine
or paracrine sources in a pre-tumorigenic state. The rea-
son for constitutive NF-kB and STAT3 activation remains
unknown. Intriguingly, NF-κB and STAT3 are known to
target Myc [34,38-41], but Myc protein was only slightly
elevated during the premalignant stage in iMycEμ mice.
Some of our other results, however, are consistent with
Myc as a target downstream of PI3K/NF-κB/STAT3 in
tumors of the iMycEμ system. Myc protein was highly ele-
vated during malignancy, and inhibition of any one of the
tested effectors of Myc transcription (PI3K, NF-κB or
STAT3) resulted in a reduction of Myc protein. Moreover,
a loss of Myc activity trailed the reduction of NF-κB and
STAT3 activity after PI3K was inhibited in iMycEμ-1 cells.
If Myc is upregulated by NF-κB and STAT3, perhaps this
occurs at some point between the premalignant and
malignant state in iMycEμ B cells. Elucidating the nature
of this apparent tumor progression event is ongoing in
our laboratory, and will be the subject of a future manu-
script.
Conclusions
In summary, we provide evidence that PI3K, NF-κB and
STAT3 are interconnected in iMycEμ B cell lymphoma.
Constitutive NF-κB and STAT3 activity are dependent
upon one another, and both also depend on heightened
PI3K activity. Signaling through each of these three mole-
cules is required for tumor maintenance and Myc expres-
sion, and combined inhibition results in additive
suppression of tumor growth. These findings, together
with the fact that NF-κB and STAT3 physically associate
with one another in the same complex, support the asser-
tion that NF-κB and STAT3 converge downstream of
PI3K in the development of iMycEμ B-cell lymphoma. Our
results underscrore the importance of further examina-
tion of crosstalk between NF-κB, STAT3 and PI3K in the
development of Myc-driven B-cell neoplasia.
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Additional file 1 NF-κB and STAT3 are constitutively activated in 
splenic B cells of young iMycEμ mice. (A and B) EMSA showing an increase 
in DNA-binding for NF-κB (A) and STAT3 (B), respectively, beginning at one 
month of age and continuing through four months of age. Nuclear extracts 
from BL6-derived splenic B cells were used as a control (C).
Additional file 2 The Myc probe is specific. (A) EMSA competition assay 
showing that 30-fold excess unlabeled probe successfully competes for 
Myc DNA-binding but a mutated probe does not. (B) Super-shift assay 
showing a loss of Myc DNA-binding that is specific for the Myc Ab but not 
for STAT3, p 50 or p 65 Abs.
Additional file 3 AKT is activated but PTEN message does not change 
in LBLs or iMycEμ-1 cells. (A) Western blotting reveals the levels of total 
AKT protein and of phosphorylated AKT (S473 and T308) in the same sam-
ples, as in Figure 6B of Han et al. (2009). (B) Quantitation of PTEN mRNA, as 
shown in Figure 6C of Han et al. (2009).
Additional file 4 Inhibition of the PI3K pathway induces growth arrest 
and apoptosis of iMycEμ-1 cells. (A) MTS/PMS anlysis reveals a dose-
dependent decrease in cell proliferation after cells are treated with LY. Data 
were normalized to DMSO-treatment controls, and error bars represent the 
standard deviation from a representative experiment performed in tripli-
cate. (B) DNA fragmentation was observed after treatment with LY, but not 
Rap, PD or SB, respectively. (C) Flow cytometry-based analyses of DNA con-
tent (PI; top row), as well as Annexin V (middle row) and cleaved caspase 3 
(bottom row) levels, showing that treatment with PD, SB or Rap (open gray 
histogram) did not result in significant differences from untreated controls 
(filled black histogram). Treatments were for 24 hours and the inhibitor con-
centrations are indicated.
Additional file 5 Wehi 231cells are very similar to iMycEμ-1 cells with 
regard to NF-κB, STAT3 and PI3K signaling. (A) EMSA showing constitu-
tive activation of NF-κB, STAT3 and Myc in mouse BCL cell lines, as indicated. 
"C" denotes control BL6 splenic B cells. (B) Western blot comparing protein 
levels of AKT, P-AKT (S473 and T308), PTEN and α-tubulin in mouse BCL 
lines, as indicated. (C) MTS/PMS assay for proliferation of designated mouse 
BCL lines after treatment with vehicle control, LY, PD, SB, AEG, Rap, LC or 
WHI for 24 hours at the given concentrations. Data were normalized to 
DMSO controls, and error bars represent the standard deviation from a rep-
resentative experiment performed in triplicate.
Additional file 6 In Wehi 231 cells, crosstalk among NF-κB, STAT3 and 
PI3K appears to regulate Myc. (A) EMSA revealing that binding of NF-κB, 
STAT3 and Myc to DNA is sensitive to inhibition of PI3K (LY), NF-κB (LC), 
STAT3 (WHI) and JNK (AEG), but not PD, SB or Rap. (B) NF-κB, STAT3 and Myc 
DNA-binding activity is reduced in a time-dependent manner after PI3K is 
inhibited with LY. (C and D) EMSA super-shift assays performed with STAT3-
specific probes and NF-κB-specific Abs (C) or NF-κB-specific probes and 
STAT3-specific Abs (D), respectively. Abs were specific for subunits of NF-κB, 
Tyr-705 phosphorylated STAT3 (P-STAT3) and total STAT3 as indicated. SP1 
and Myc Abs were used as negative controls. (E) Co-IP and Western blot 
showing co-immunoprecipitation of NF-κB p50 and P-STAT3. Abs used for 
immunoprecipitations (IP) and Western blotting (WB) are designated. The 
incubation time with small-molecule inhibitors was 24 hours unless other-
wise noted.
Additional file 7 Co-treatment with small-molecule inhibitors of NF-
κB, STAT3 and/or PI3K additively inhibits proliferation of Wehi 231 
cells. MTS/PMS cell proliferation assay after cell treatment with low doses of 
LY, LC and WHI, either in isolation or in various combinations, for 24 hours. 
Box at bottom gives the average percent (%) growth inhibition. Data were 
normalized to DMSO controls, and error bars represent the standard devia-
tion from a representative experiment performed in triplicate.Han et al. Molecular Cancer 2010, 9:97
http://www.molecular-cancer.com/content/9/1/97
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